NETS

Chubb’s Jenn Guerrini Named NETS Board Vice Chairperson for 2023 and Board Chairperson for 2024

Retrieved on: 
화요일, 1월 31, 2023
Automotive Manufacturing, Aerospace, Supply Chain Management, Manufacturing, Education, Urban Planning, Landscape, Social Media, Mobile, Wireless, Other Construction & Property, Transportation, Commercial Building & Real Estate, Construction & Property, Travel, Other Transport, Trucking, Building Systems, Communications, Transport, General Automotive, Telecommunications, Retail, Automotive, Technology, Public Transport, Agriculture, Natural Resources, Training, Other Manufacturing, Oil, Gas, Textiles, Steel, Packaging, Energy, Engineering, Chemicals, Plastics, Insurance, Safety, Chubb, Network, Chairperson, Employment, Chair, NETS, Management, Olindo Guerrini

The Network of Employers for Traffic Safety (NETS) is pleased to announce the election of Jenn Guerrini, Vice President, Executive Auto Specialist, Risk Engineering Services, Chubb, as NETS Board Vice Chairperson for 2023.

Key Points: 
  • The Network of Employers for Traffic Safety (NETS) is pleased to announce the election of Jenn Guerrini, Vice President, Executive Auto Specialist, Risk Engineering Services, Chubb, as NETS Board Vice Chairperson for 2023.
  • Following the Vice Chair position, Guerrini will then assume the role of NETS Board Chairperson starting in 2024 for a two-year term.
  • “I am delighted that Jenn Guerrini will continue Chubb’s on-going support of NETS and our road safety mission as she assumes the new Board Vice Chair in 2023 and Chair position in 2024,” said Susan Hipp, Executive Director of NETS.
  • “Jenn brings energy and experience to NETS and understands the important role employers can play in making our roads safer.

Viewpoint Molecular Targeting Announces First Neuroendocrine Tumor Patients Dosed with Therapeutic Intent

Retrieved on: 
월요일, 1월 23, 2023
Neurology, FDA, Clinical Trials, Other Health, Biotechnology, Radiology, General Health, Pharmaceutical, Health, Oncology, Glomus tumor, Hospital, Isotope, Diagnosis, Professional, Safety, Patient, NET, Food, Neoplasm, Viewpoint, Nuclear medicine, SSTR2, Partnership, Fortis Healthcare, NETS, Observation, Cancer, Medical imaging, Pharmaceutical industry, Medical device

Viewpoint Molecular Targeting®, Inc., a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents, today announced the first dosing of two neuroendocrine tumor patients with therapeutic intent.

Key Points: 
  • Viewpoint Molecular Targeting®, Inc., a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents, today announced the first dosing of two neuroendocrine tumor patients with therapeutic intent.
  • VMT-α-NET, which is being developed for the treatment and diagnosis of somatostatin receptor subtype 2 (SSTR2) expressing neuroendocrine tumors, was administered to the patients in early December.
  • The dosed patients were diagnosed with confirmed-advanced somatostatin expressing neuroendocrine tumors (NETs).
  • No acute adverse reactions were observed in the first 10 days post administration and patients remain stable and in good condition.

GreenPower Appoints New England Truck Solutions as Dealer for Medium and Heavy-Duty Commercial Electric Vehicles

Retrieved on: 
목요일, 2월 16, 2023
NETS, Green, Ford F-Series (medium duty truck), Sale, EVS, EV, Partnership, Chassis, Rail transport

(NASDAQ: GP) (TSXV: GPV) ("GreenPower"), a leading manufacturer and distributor of purpose-built, all-electric, zero-emission medium and heavy-duty vehicles serving the cargo and delivery market, shuttle and transit space and school bus sector, today announced the appointment of New England Truck Solutions (NETS) as a dealer for GreenPower's medium and heavy-duty commercial vehicles in the Boston and Rhode Island markets.

Key Points: 
  • (NASDAQ: GP) (TSXV: GPV) ("GreenPower"), a leading manufacturer and distributor of purpose-built, all-electric, zero-emission medium and heavy-duty vehicles serving the cargo and delivery market, shuttle and transit space and school bus sector, today announced the appointment of New England Truck Solutions (NETS) as a dealer for GreenPower's medium and heavy-duty commercial vehicles in the Boston and Rhode Island markets.
  • Under the new dealership agreement with GreenPower, the company will be able to make its first EV offerings to NETS customers through the sale of GreenPower's medium and heavy-duty commercial vehicles.
  • In this partnership, GreenPower will help New England Truck Solutions educate and introduce the benefits of GreenPower all-electric vehicles to their customers and facilitate the necessary provisions that go hand-in-hand for ownership of all-electric commercial vehicles.
  • "GreenPower and New England Truck Solutions share common values in providing unprecedented customer service and providing its customers a one-stop shop for commercial EVs."

ORYZON Announces First Patient In in NET, a Collaborative Phase II Basket Study With Iadademstat in R/R Patients With Neuroendocrine Carcinomas

Retrieved on: 
수요일, 1월 18, 2023
NEC Laboratories America, Prognosis, LSD1, Cancer, AML, Acute myeloid leukemia, Phases of clinical research, Assistant Chief of the Air Staff, Safety, Azacitidine, MD, FDA, Squamous cell carcinoma, ALICE, Hematological Cancer Research Investment and Education Act, Genomics, B cell, ASH, NETS, Patient, Survival, Prevalence, ORY, Fox Chase Cancer Center, FCCC, Research, ORR, ISIN, Paclitaxel, Gastrointestinal tract, NEC, Pharmaceutical industry, SCLC, EU

The trial will assess the safety and efficacy of iadademstat in combination with paclitaxel in patients with relapsed/refractory small cell lung cancer or extrapulmonary high grade NECs.

Key Points: 
  • The trial will assess the safety and efficacy of iadademstat in combination with paclitaxel in patients with relapsed/refractory small cell lung cancer or extrapulmonary high grade NECs.
  • Neuroendocrine neoplasms are rare and heterogeneous cancers arising from neuroendocrine cells, representing 0.5% of all newly diagnosed malignancies, with a prevalence of 100,000 cases in the US.
  • Patients often rapidly develop progressive disease after first line cytotoxic chemotherapy and lack clearly efficacious second line treatment options.
  • Iadademstat has orphan drug designation for SCLC in the US and for AML in the US and EU.

CANON INNOVATIONS PUSH THE BOUNDARIES OF STORYTELLING WITH A FIRST-OF-ITS-KIND IMMERSIVE MOVIE EXPERIENCE AT CES® 2023

Retrieved on: 
화요일, 1월 3, 2023
EOS, United States Patent and Trademark Office, NBA, NYSE, Mandalay Bay Convention Center, Woman, News, PST, POV, Canon Cinema EOS, 3D, Canon Inc., Virtual reality, Domestic worker, Universal Pictures, RSS, NETS, Patent, VR, Perception, Culture, Facial recognition, Family, Communication, Fortune (magazine), Alfred Pennyworth, Lens, Little, Barclays Center, Sound, Life, Religion, U.S.A, Las Vegas Convention Center, Binary relation, Home page, Friends, Multimedia, Parent, Software, Sale, Education, Music, PTZ, Cavalier, Conference, Medicine, CES, Video game console, Camera, Entertainment, Newsweek, Cabin, Canon

MELVILLE, N.Y., Jan. 3, 2023 /PRNewswire/ -- Canon U.S.A., Inc., a leader in digital imaging solutions, pushed innovation to new heights in 2022. At CES 2023, the company will demonstrate how its technology is working to help dissolve limits between real and virtual worlds through a first-of-its-kind immersive movie experience that will place attendees inside of the story. With the launch of the theme 'Limitless Is More,' and Canon's latest imaging innovations, CES attendees will be able to fully immerse themselves into M. Night Shyamalan's upcoming Universal Pictures thriller, Knock at the Cabin (in theaters February 3). Canon will prove how its solutions can remove the limits humanity faces to create more meaningful communication, more powerful collaboration, more exciting perspectives, and more boundless imagination across four unique technologies.

Key Points: 
  • MELVILLE, N.Y., Jan. 3, 2023 /PRNewswire/ -- Canon U.S.A., Inc., a leader in digital imaging solutions, pushed innovation to new heights in 2022.
  • With Kyosei as the driving force, Canon's immersive experience and featured technologies at CES 2023 will show attendees how the company looks to contribute to society and have a positive impact.
  • Kokomo is a first of its kind immersive virtual reality software^, designed to change human communication by combining virtual reality with an immersive calling experience.
  • The result is an immersive and customizable viewing experience from perspectives that may not be possible with traditional camera systems.

North America Nuclear Medicine Market Report 2022: Government Funding and Initiatives for New Techniques Drive Sector Growth - ResearchAndMarkets.com

Retrieved on: 
금요일, 12월 9, 2022
Medical Devices, Health, Curium, Therapy, Agent handling, Somatostatin, Time of flight, US FDA, Disease, Copper (64Cu) oxodotreotide, Atmosphere, PET, COVID-19, Diagnosis, Patient, Prevalence, Cancer, Nuclear medicine, Research, Breast cancer, Radionuclide, Google Images, Radiopharmaceutical, Government, US Foods, NETS, Coronavirus, Medicare, Mortality, CAD, USD, Risk, Pharmaceutical industry, Medical imaging, Medical device, Growth

The "North America Nuclear Medicine Market - Growth, Trends, COVID-19 Impact, and Forecast (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Nuclear Medicine Market - Growth, Trends, COVID-19 Impact, and Forecast (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.
  • The North American nuclear medicine market was valued at USD 5,624 million in 2021.
  • These statistics suggest that nuclear imaging, along with other imaging techniques, decreased, impacting the market size and trends.
  • Government initiatives and funding for developing new techniques are estimated to drive the nuclear medicine market.

Patients and Doctors Agree on Treatment Goals Only Half the Time, According to JNCCN Study on People with Neuroendocrine Tumors

Retrieved on: 
월요일, 12월 12, 2022
Oncology, Associate professor, Fox Chase Cancer Center, Prostate, Health, Cancer, Professor, Neoplasm, NCCN, Policy, Patient, Associate, SCM, City, Pharmacist, Wilms' tumor, Pharmacology, Fatigue, Duke Cancer Institute, University of Michigan Rogel Cancer Center, Bioethics, MPH, University, National Comprehensive Cancer Network, Dizziness, MD Anderson Cancer Center, Overalls, NETS, Education, MBA, Harborside, Report, Hematology, JD, Chair, Internal medicine, Haematopoietic system, City of Hope, Communication, Duke University Hospital, Mayo Clinic Cancer Center, UCSF, Strathcona County, Survival, Caregiver, UCSF Helen Diller Family Comprehensive Cancer Center, Life expectancy, Public policy, Medical imaging, Pharmaceutical industry, Research, Epidemiology, MD, Medicine, Hope, UAB, Doctor of Philosophy

PLYMOUTH MEETING, Pa., Dec. 12, 2022 /PRNewswire/ -- New research from cancer research and treatment organization City of Hope in the December 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that only 30% of patients with advanced neuroendocrine tumors (NETs) say their top goal for treatment is living longer. The remaining patients selected other single specific treatment goals as most important, such as maintaining the ability to do daily activities, reducing or eliminating pain, or reducing or eliminating symptoms like fatigue. 66.7% of those surveyed agreed with the statement: "I would rather live a shorter life than lose my ability to take care of myself."

Key Points: 
  • However, respondents felt their doctors were more singularly focused on extending overall survival, even if it impacted other outcomes.
  • Only 51.7% of patients perceived that they had the same treatment goals as their physician.
  • Complimentary access to " Patient-Defined Goals and Preferences Among Adults With Advanced Neuroendocrine Tumors " is available until March 10, 2023.
  • The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation .

Patients and Doctors Agree on Treatment Goals Only Half the Time, According to JNCCN Study on People with Neuroendocrine Tumors

Retrieved on: 
월요일, 12월 12, 2022
Oncology, Associate professor, Fox Chase Cancer Center, Prostate, Health, Cancer, Professor, Neoplasm, NCCN, Policy, Patient, Associate, SCM, City, Pharmacist, Wilms' tumor, Pharmacology, Fatigue, Duke Cancer Institute, University of Michigan Rogel Cancer Center, Bioethics, MPH, University, National Comprehensive Cancer Network, Dizziness, MD Anderson Cancer Center, Overalls, NETS, Education, MBA, Harborside, Report, Hematology, JD, Chair, Internal medicine, Haematopoietic system, City of Hope, Communication, Duke University Hospital, Mayo Clinic Cancer Center, UCSF, Strathcona County, Survival, Caregiver, UCSF Helen Diller Family Comprehensive Cancer Center, Life expectancy, Public policy, Medical imaging, Pharmaceutical industry, Research, Epidemiology, MD, Medicine, Hope, UAB, Doctor of Philosophy

PLYMOUTH MEETING, Pa., Dec. 12, 2022 /PRNewswire/ -- New research from cancer research and treatment organization City of Hope in the December 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that only 30% of patients with advanced neuroendocrine tumors (NETs) say their top goal for treatment is living longer. The remaining patients selected other single specific treatment goals as most important, such as maintaining the ability to do daily activities, reducing or eliminating pain, or reducing or eliminating symptoms like fatigue. 66.7% of those surveyed agreed with the statement: "I would rather live a shorter life than lose my ability to take care of myself."

Key Points: 
  • However, respondents felt their doctors were more singularly focused on extending overall survival, even if it impacted other outcomes.
  • Only 51.7% of patients perceived that they had the same treatment goals as their physician.
  • Complimentary access to " Patient-Defined Goals and Preferences Among Adults With Advanced Neuroendocrine Tumors " is available until March 10, 2023.
  • The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation .

TerSera® to sponsor "NET Cancer Health Storylines" digital platform to support patients suffering from Carcinoid Syndrome Diarrhea

Retrieved on: 
수요일, 12월 7, 2022
Therapy, Carcinoid syndrome, Mnet, Flatulence, Angioedema, Headache, Impact of the COVID-19 pandemic, CYP3A4, Patient, History, Contraindication, Anxiety, Hormone, Carcinoid, Rash, Union, Wilms' tumor, Partnership, Perforated ulcer, Medication, Fatigue, Defecation, Abdominal pain, Clinical trial, Constipation, Serotonin, Itch, Google Play, Learning, Diarrhea, SSA, Liver, Bradykinin, CYP2B6, Health, Quality of life, Absorption, NETS, Water, Medtech, Obstruction, CCF, Peripheral edema, Drug, Nausea, FDA, App Store (iOS/iPadOS), CSD, Depression, NET, Appetite, Pharmaceutical industry, Generic drug, Telotristat ethyl, Fever, Biotechnology, Pharma, CS

"We are grateful for this support from TerSera to continue to enhance the NET Health Storylines platform to distribute meaningful educational content to NETs patients.

Key Points: 
  • "We are grateful for this support from TerSera to continue to enhance the NET Health Storylines platform to distribute meaningful educational content to NETs patients.
  • The resources available through this platform are important tools in supporting NET patients throughout their journey," said Keith Warner, Chief Executive Officer of the Carcinoid Cancer Foundation.
  • "Collaborating with CCF and the NET Cancer Health Storylines platform is a fantastic opportunity for us to support patients with Carcinoid Syndrome Diarrhea beyond our existing clinical nurse educator program.
  • The Carcinoid Cancer Foundation is the oldest nonprofit carcinoid and neuroendocrine cancer organization in the United States, founded in 1968.

Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis

Retrieved on: 
화요일, 11월 15, 2022
Marketing, Drug resistance, AACR, Head, Attention, PD-1, Food, Conference, Cancer, PDAC, DNA, Poster, Bristol Myers Squibb, Wilms' tumor, American Association for Cancer Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Legislation, Neutrophil, Neoplasm, Tumor microenvironment, Annual report, CEACAM1, Nivolumab, SCCHN, Metastasis, Drug development, Patent, CM24, Cetuximab, Risk, Research, STAT3, NETS, NET, Survival, Trial of the century, Escape Room, HIV disease progression rates, Pharmaceutical industry

REHOVOT, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced that it is presenting data that provide a strong rationale for advancing CM24 as an anti-cancer, anti-metastatic agent.  The poster, entitled “CM24, a Novel Anti-CEACAM1 mAb, Suppresses Neutrophil Extracellular Trap (NET)-induced Migration and Metastasis of Cancer Cells,” is presented at the American Association of Cancer Research (AACR) Special Conference: Cancer Metastasis, taking place in Portland, Oregon, US, on November 14-17, 2022.

Key Points: 
  • The poster, entitled CM24, a Novel Anti-CEACAM1 mAb, Suppresses Neutrophil Extracellular Trap (NET)-induced Migration and Metastasis of Cancer Cells, is presented at the American Association of Cancer Research (AACR) Special Conference: Cancer Metastasis, taking place in Portland, Oregon, US, on November 14-17, 2022.
  • NET-associated CEACAM1 constitutes adhesion focal for cancer cells and, therefore, is suggested as a potential therapeutic target for preventing metastatic progression.
  • The preclinical data show that CM24 binds to the NET structure, significantly suppressing NET-induced cancer cell migration and inhibiting cancer metastasis in mouse models.
  • These data demonstrate the potential of CM24 as a powerful treatment for patients with cancer, said Gil Efron, Chief Executive Officer, Purple Biotech.